Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study Talquetamab + teclistamab in patients with triple-class exposed R/R MM and EMD: The RedirecTT-1 study June 2025 Congress News Read more
2022 April Clinical trials FDA approval for axicabtagene ciloleucel as second-line therapy for LBCL patients Read more
2022 April Science Novel genetic variants of PTPRG gene in TK inhibitor-resistant chronic myeloid leukaemia Read more
2022 April Prevention Immune response memory in patients after one year of COVID-19 infection Read more
2022 April Science Cardiovascular mortality in cancer survivors more likely than in the general population Read more
2022 April Pharma News Axicabtagene ciloleucel shows promise as frontline therapy for high-risk large B-cell lymphoma Read more
2022 March Clinical trials Phase 3 trial examining gene therapy for haemophilia A shows promising results Read more
Top
